# Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)

> **NCT02741557** · PHASE1 · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 118 (actual)

## Conditions studied

- Infection, Human Immunodeficiency Virus
- HIV Infections

## Interventions

- **DRUG:** DTG
- **DRUG:** RPV
- **DRUG:** DTG/RPV FDC

## Key facts

- **NCT ID:** NCT02741557
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-11
- **Primary completion:** 2016-10-24
- **Final completion:** 2016-10-24
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2019-07-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02741557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02741557, "Bioequivalence Study of a Fixed-dose Combination (FDC) of Dolutegravir (DTG) and Rilpivirine (RPV)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02741557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*